FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/01/2026
Voltar para busca
Dado oficial do USPTO
ACELLYTRON
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ACELLYTRON
ST13
US500000079392046Classe
5, 35, 42, 44
Pedido
79392046
Registro
7830495
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
31
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 42, 44
Data de depósito
28/11/2023
Data de registro
17/06/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
17/06/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
CN
Examinador
THOMAS, JULIE
Unidade examinadora
L70
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Wuxi Biologics (Shanghai) Co., Ltd.
Representantes
Michael T. Smith Birch Stewart Kolasch & Birch LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Chemical-pharmaceutical preparations for the treatment of blood cancersolid tumorcancer or tumorautoimmune diseasenon-communicable diseasesNeurodegenerative diseasesaging-related diseasescoagulation disorder and infectious disease; biochemical medicines for the treatment of blood cancersolid tumorcancer or tumorautoimmune diseasenon-communicable diseasesNeurodegenerative diseasesaging-related diseasescoagulation disorder and infectious disease; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes for the treatment of blood cancersolid tumorcancer or tumorautoimmune diseasenon-communicable diseasesNeurodegenerative diseasesaging-related diseasescoagulation disorder and infectious disease; drugs for medical purposesnamely medicines for the treatment of blood cancersolid tumorcancer or tumorautoimmune diseasenon-communicable diseasesNeurodegenerative diseasesaging-related diseasescoagulation disorder and infectious disease; pharmaceutical preparations for the treatment of blood cancersolid tumorcancer or tumorautoimmune diseasenon-communicable diseasesNeurodegenerative diseasesaging-related diseasescoagulation disorder and infectious disease; drugs for treatment of cancer; medical preparation for treating diseases and disorders related to the immune system; biological agentnamely biologic preparations for treating cancer; pharmaceutical preparations for the prevention and treatment of cancer; living cells for medical use; oncolytic viral therapies; medical cell inhibitornamely proteinantibody and small molecule inhibitor; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; pharmaceutical preparationsnamely tumor suppressor; cells for medical use; dietetic food and substances adapted for medical use; biological preparations for veterinary purposes for the treatment of blood cancersolid tumorcancer or tumorautoimmune diseasenon-communicable diseasesNeurodegenerative diseasesaging-related diseasescoagulation disorder and infectious disease
Classe 35
Online advertising on a computer network; advertising services; publicity agents; dissemination of advertising and advertising matter in the nature of flyersprospectusesbrochuresleaflets and samples; providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing; sponsorship search; retail store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies
Classe 42
Research and development of new products for others; technological research in the field of pharmaceutical studiescell separation and cell culture; chemical analysis; biochemistry research and analysis; research and development in the field of pharmaceutical preparations; medical research service; research and development services in the field of antibodies; stem cell research services; medical research; medical and scientific researchnamely conducting clinical trials for others; biological research; computer programming in the field of medical aspects
Classe 44
Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; providing medical information; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistance
Publicações
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/01/2026
FIMP
FINAL DISPOSITION PROCESSED
14/01/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
17/09/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/09/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/08/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
20/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
17/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
17/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/04/2025
PUBO
PUBLISHED FOR OPPOSITION
29/04/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
23/04/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/04/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
21/02/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/02/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
21/02/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
13/01/2025
GNFR
FINAL REFUSAL E-MAILED
13/01/2025
CNFR
FINAL REFUSAL WRITTEN
13/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/10/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/10/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/10/2024
RFNT
REFUSAL PROCESSED BY IB
11/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
18/07/2024
RFRR
REFUSAL PROCESSED BY MPU
18/07/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/06/2024
CNRT
NON-FINAL ACTION WRITTEN
26/06/2024
DOCK
ASSIGNED TO EXAMINER
26/06/2024
MAFR
APPLICATION FILING RECEIPT MAILED
27/03/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/03/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
21/03/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACELLYTRON ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.